Drugs / ETBX-051
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT03481816 | Jul 2018 → Jan 2020 | prostate cancer | National Cancer Institute (NCI) | Completed | Met primary |
| Phase 1 | NCT03384316 | Jan → May 2018 | breast cancer, colon carcinoma, lung cancer, prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT04247282 | Jun 2020 → Aug 2021 | head and neck cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03563157 | Sep 2018 → Apr 2019 | colorectal cancer | ImmunityBio, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03647423 | Aug 2018 → Aug 2020 | chordoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169777 | Aug 2018 → Jan 2019 | colorectal cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03586869 | Jul 2018 → Apr 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03563170 | May 2018 → Aug 2019 | hepatocellular carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03169738 | Feb 2018 → Jan 2019 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03387111 | Jan 2018 → Apr 2019 | squamous cell carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03197584 | Dec 2017 → Feb 2019 | ovarian carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03167164 | Dec 2017 → Jan 2019 | cutaneous neuroendocrine carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169764 | Dec 2017 → Jan 2019 | head and neck squamous cell carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03175666 | Dec 2017 → Jan 2019 | triple-negative breast carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03197571 | Dec 2017 → Jan 2019 | urothelial carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03554109 | Sep 2018 → Jun 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03563144 | Aug 2018 → Dec 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03574649 | Jun → Aug 2018 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT03387085 Background | Mar 2018 → Sep 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03167177 Background | Dec 2017 → Jan 2019 | melanoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETBX-051 | “Treatment regimen: 5 × 1011 viral particles once, subcutaneously of each component of the Tri-Ad5 vaccine (ETBX-011, ETBX-061, and ETBX-051 targeting tumor-associated antigens...” PMID 40156838 ↗ Mar 202519“A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab,...” NCT03647423 ↗ |
| Modality | Vaccine | “Ad5 [E1-, E2b-]-Brachyury vaccine” NCT03169738 ↗ |
| Route | Subcutaneous | “The ETBX-051, ETBX-61 and ETBX-71 vaccines will be administered subcutaneously (SC)” NCT03481816 ↗ |